Pharma’s R&D, commercial approach shifts amid global policy evolution

A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE. A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE. A new survey from Numerof & Associates has highlighted the changes that global policy changes are making to the pharma commercial and R&D strategy. Credit: izzuanroslan / Shutterstock.com. A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch of high-priced, speciality products outside of the US amid a…

Source: Clinical Trials Arena